fbpx Yourgene Health plc - Home
Image is not available
Expertise  / Partnership / Comprehensive
Image is not available
Expertise  / Partnership / Comprehensive
Image is not available
Expertise  / Partnership / Comprehensive
previous arrow
next arrow
Slider
Infectious Disease
Clarigene RUO
Clarigene CE-IVD
Clarigene SARS-CoV-2 CE-IVD
Clarigene™ Feature Notes
NIPT
IONA® Nx
For Clinical Laboratories
Overview
Workflow
Clinical Performance
Benefits of the IONA® Nx NIPT Workflow
Instruments
IONA® Software
Atlas Workflow Manager
MyNIPT®
Technical Support
Quality and Regulatory
Choose IONA® Nx NIPT Workflow
the IONA® test
For Clinical Laboratories
Overview
Technology
CE-IVD
Clinical Performance
Results
MyNIPT®
Application Support
FAQs
Choose IONA®
Laboratory Customer Login
For Pregnant Women
Overview
What is NIPT?
How does it work?
Performance Characteristics
Who can have the IONA® Test
Results
Where can I get the IONA® test?
UK & Ireland Locations
Nordic Locations
Rest of World Locations
FAQs
For Healthcare Professionals
Overview
Background
Clinical Performance
Results
MyNIPT®
Who can have the IONA® Test
FAQs
Responsible Screening
Choose IONA®
Resources
Contact Us
Sage™ Prenatal Screen
For Clinical Laboratories
Overview
Technology
Clinical Performance
Results
Choose Sage™
Sage QS 32plex
For Pregnant Women
Advantages of the Sage™ prenatal screen
Overview
Who can have the Sage™ test
Results
For Healthcare Professionals
Overview
Background
Who can have the Sage™ test
Results
Clinical Performance
Contact Us
Reproductive Health
Cystic Fibrosis
Cystic Fibrosis Analysis
Choose CF-EU2
Male Infertility
Pregnancy Loss
Rapid Aneuploidy Analysis
Thrombosis Risk Panel
Precision Medicine
Elucigene DPYD
DPYD Overview
DPYD Testing Workflow
Clinical Performance
Choose Elucigene DPYD
Yourgene Flex™
Platforms
Yourgene® QS250
Yourgene® SP150

Test performance observed following validation metrics for singleton and twin pregnancies

IONA® Nx validation studya
 SensitivitySpecificity
Trisomy 21

>99.99%
(46/46)
95% CI: 92.3 - 100%

>99.99% 
(426/426)
95% CI: 99.1 – 100%

Trisomy 18

>99.99%
(20/20)
95% CI: 83.2 – 100%

>99.99%
(452/452)
95% CI: 99.2 – 100%

Trisomy 13

>99.99%
(10/10)
95% CI: 69.2 – 100%

>99.99%
(462/462)
95% CI: 99.2 – 100%

a The Validation performance has been demonstrated by evaluating 472 clinical samples from singleton and twin pregnancy and comparing to a reference result of an amniocentesis or chorionic villus sampling (CVS) sample or a birth outcome.

 

Condition

Sensitivity

Specificity

XO
(Turner Syndrome)

>99.99%
(15/15)
95% CI: 78.2 – 100%

>99.99%
(428/428)
95% CI: 99.1 – 100%

XXY
(Klinefelter syndrome)

>99.99%
(4/4)
95% CI: 39.8 – 100%

99.5%
(437/439)
95% CI: 98.4 – 99.9%

XYY
(XYY Syndrome)

N/A

>99.99%
(443/443)
95% CI: 99.2 – 100%

XXX
(Trisomy X)

>99.99%
(1/1)
95% CI: 2.5 – 100%

>99.99%
(442/442)
95% CI: 99.2 – 100%

Trisomy

>99.9%
(3/3)
95% CI: 29.2 – 100%

99.3%
(439/442)
95% CI: 98.0 – 99.9%

Monosomy

N/A

>99.9%
(442/442)
95% CI: 99.2 – 100%

The Validation performance has been demonstrated by evaluating 443 clinical samples from singleton and comparing to a reference result of an amniocentesis or chorionic villus sampling (CVS) sample or a birth outcome.

This has been demonstrated using the IONA® Nx cfDNA Library Preparation DX kit and the IONA® analysis software version 2.0.2. Data held on file by Yourgene Health Plc.